Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease

NCT01496313 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01496313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01496313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
June 8, 2012
Completion date
July 11, 2024
Enrollment
81 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer